INTERIM RESULTS FROM A PHASE 1B DOSE-ESCALATION STUDY OF 4 WEEKS OF PEG-INTERFERON LAMBDA (PEG-RIL-29) TREATMENT IN SUBJECTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 1 WITH PRIOR VIROLOGIC RESPONSE AND RELAPSE TO PEGINTERFERON ALFA AND RIBAVIRIN
Publication
, Conference
Lawitz, EJ; Zaman, A; Muir, AJ; Shiffman, ML; Yoffe, B; Zhang, T; Souza, S; Hausman, DF
Published in: HEPATOLOGY
October 1, 2008
Duke Scholars
Published In
HEPATOLOGY
ISSN
0270-9139
Publication Date
October 1, 2008
Volume
48
Issue
4
Start / End Page
385A / 385A
Location
San Francisco, CA
Publisher
JOHN WILEY & SONS INC
Conference Name
59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics
Citation
APA
Chicago
ICMJE
MLA
NLM
Lawitz, E. J., Zaman, A., Muir, A. J., Shiffman, M. L., Yoffe, B., Zhang, T., … Hausman, D. F. (2008). INTERIM RESULTS FROM A PHASE 1B DOSE-ESCALATION STUDY OF 4 WEEKS OF PEG-INTERFERON LAMBDA (PEG-RIL-29) TREATMENT IN SUBJECTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 1 WITH PRIOR VIROLOGIC RESPONSE AND RELAPSE TO PEGINTERFERON ALFA AND RIBAVIRIN. In HEPATOLOGY (Vol. 48, pp. 385A-385A). San Francisco, CA: JOHN WILEY & SONS INC.
Lawitz, Eric J., Atif Zaman, Andrew J. Muir, Mitchell L. Shiffman, Boris Yoffe, Tracy Zhang, Sherri Souza, and Diana F. Hausman. “INTERIM RESULTS FROM A PHASE 1B DOSE-ESCALATION STUDY OF 4 WEEKS OF PEG-INTERFERON LAMBDA (PEG-RIL-29) TREATMENT IN SUBJECTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 1 WITH PRIOR VIROLOGIC RESPONSE AND RELAPSE TO PEGINTERFERON ALFA AND RIBAVIRIN.” In HEPATOLOGY, 48:385A-385A. JOHN WILEY & SONS INC, 2008.
Lawitz EJ, Zaman A, Muir AJ, Shiffman ML, Yoffe B, Zhang T, et al. INTERIM RESULTS FROM A PHASE 1B DOSE-ESCALATION STUDY OF 4 WEEKS OF PEG-INTERFERON LAMBDA (PEG-RIL-29) TREATMENT IN SUBJECTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 1 WITH PRIOR VIROLOGIC RESPONSE AND RELAPSE TO PEGINTERFERON ALFA AND RIBAVIRIN. In: HEPATOLOGY. JOHN WILEY & SONS INC; 2008. p. 385A-385A.
Lawitz, Eric J., et al. “INTERIM RESULTS FROM A PHASE 1B DOSE-ESCALATION STUDY OF 4 WEEKS OF PEG-INTERFERON LAMBDA (PEG-RIL-29) TREATMENT IN SUBJECTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 1 WITH PRIOR VIROLOGIC RESPONSE AND RELAPSE TO PEGINTERFERON ALFA AND RIBAVIRIN.” HEPATOLOGY, vol. 48, no. 4, JOHN WILEY & SONS INC, 2008, pp. 385A-385A.
Lawitz EJ, Zaman A, Muir AJ, Shiffman ML, Yoffe B, Zhang T, Souza S, Hausman DF. INTERIM RESULTS FROM A PHASE 1B DOSE-ESCALATION STUDY OF 4 WEEKS OF PEG-INTERFERON LAMBDA (PEG-RIL-29) TREATMENT IN SUBJECTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 1 WITH PRIOR VIROLOGIC RESPONSE AND RELAPSE TO PEGINTERFERON ALFA AND RIBAVIRIN. HEPATOLOGY. JOHN WILEY & SONS INC; 2008. p. 385A-385A.
Published In
HEPATOLOGY
ISSN
0270-9139
Publication Date
October 1, 2008
Volume
48
Issue
4
Start / End Page
385A / 385A
Location
San Francisco, CA
Publisher
JOHN WILEY & SONS INC
Conference Name
59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics